Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ascendis Pharma A/S (ASND)
Price$268.83Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €720.1M | €363.6M | €266.7M | €51.2M | €7.8M | €7.0M | €13.4M | €10.6M | €1.5M | €4.6M | €8.1M |
| Gross profit | €625.2M | €319.4M | €222.3M | €39.0M | €4.3M | €7.0M | €13.4M | — | — | — | — |
| Gross margin | 86.82% | 87.83% | 83.36% | 76.28% | 54.71% | 100.00% | 100.00% | — | — | — | — |
| Research & development | €303.6M | €307.0M | €413.5M | €379.6M | €295.9M | €260.9M | €191.6M | €140.3M | €99.6M | €66.0M | €40.5M |
| Operating expenses | €761.5M | €598.1M | €677.9M | €600.9M | €456.0M | €337.6M | €240.1M | — | — | — | — |
| Operating income | −€136.3M | −€278.8M | −€455.5M | −€561.8M | −€451.8M | −€330.6M | −€226.7M | −€154.8M | −€111.5M | −€72.9M | −€41.8M |
| Operating margin | −18.92% | −76.66% | −170.79% | −1,097.85% | −5,808.59% | −4,755.07% | −1,695.10% | −1,462.59% | −7,290.26% | −1,583.15% | −515.21% |
| EBITDA | −€119.1M | −€261.5M | −€437.1M | −€544.3M | −€436.8M | −€321.2M | −€220.0M | −€153.9M | −€110.8M | −€72.2M | −€41.3M |
| EBITDA margin | −16.53% | −71.92% | −163.89% | −1,063.63% | −5,616.43% | −4,619.19% | −1,645.09% | −1,454.28% | −7,242.29% | −1,568.45% | −508.34% |
| Net income | −€228.0M | −€378.1M | −€481.4M | −€583.2M | −€383.6M | −€419.0M | −€218.0M | −€130.1M | −€123.9M | −€68.5M | −€32.9M |
| Net profit margin | −31.67% | −103.97% | −180.51% | −1,139.63% | −4,931.56% | −6,025.53% | −1,630.03% | −1,229.53% | −8,097.84% | −1,487.30% | −405.54% |
| Basic EPSper basic share | -€3.76 | -€6.53 | -€8.55 | -€10.40 | -€7.00 | -€8.28 | -€4.69 | -€3.17 | -€3.68 | -€2.58 | -€1.39 |
| Diluted EPSper diluted share | -€3.76 | -€6.53 | -€8.55 | -€10.40 | -€7.00 | -€8.28 | -€4.69 | -€3.17 | -€3.68 | -€2.58 | -€1.39 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | 10.28M |
T. Rowe Price Investment Management, Inc. | 6.75M |
Avoro Capital Advisors LLC | 5.11M |
WESTFIELD CAPITAL MANAGEMENT CO LP | 4.8M |
Jupiter Topco LLC | 3.65M |
FMR LLC | 3.55M |
Artisan Partners Limited Partnership | 2.63M |
BlackRock, Inc. | 2.21M |
Capital International Investors | 1.99M |
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1.88M |
FRANKLIN RESOURCES INC | 1.86M |
WELLINGTON MANAGEMENT GROUP LLP | 1.55M |
AMERICAN CENTURY COMPANIES INC | 1.4M |
PERCEPTIVE ADVISORS LLC | 1.16M |
PRICE T ROWE ASSOCIATES INC /MD/ | 1.12M |
Capital World Investors | 906.08K |
PRINCIPAL FINANCIAL GROUP INC | 873.5K |
Polar Capital Holdings Plc | 616.91K |
GOLDMAN SACHS GROUP INC | 559.53K |
MORGAN STANLEY | 544.39K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 2, 2026Form 4 | SMITH SCOTT THOMASEVP & Chief Financial Officer | BuyOrdinary Shares | 100 | $219.00 | $21.9K | 4.4K |
| May 29, 2026Form 4 | BIENAIME JEAN JACQUESDirector | BuyOrdinary Shares | 100 | $223.50 | $22.4K | 900 |
| May 29, 2026Form 4 | BIENAIME JEAN JACQUESDirector | BuyOrdinary Shares | 200 | $222.30 | $44.5K | 800 |
| May 29, 2026Form 4 | BIENAIME JEAN JACQUESDirector | BuyOrdinary Shares | 200 | $223.76 | $44.8K | 600 |
| May 29, 2026Form 4 | SMITH SCOTT THOMASEVP & Chief Financial Officer | BuyOrdinary Shares | 250 | $223.32 | $55.8K | 4.3K |